Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for screening potential biomarker of prostate cancer and application thereof

A technology for biomarkers and prostate cancer, which is applied in the field of screening potential biomarkers of prostate cancer, and can solve problems such as the unclear mechanism of prostate cancer research

Active Publication Date: 2022-03-29
THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the research mechanism of the occurrence and development of prostate cancer is still unclear. Due to the high incidence of prostate cancer and its tendency to develop into castration-resistant prostate cancer, finding new therapeutic targets is still an important goal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for screening potential biomarker of prostate cancer and application thereof
  • Method for screening potential biomarker of prostate cancer and application thereof
  • Method for screening potential biomarker of prostate cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Previous studies have determined the general expression profile and function of some FGF family factors in prostate cancer. Based on this, the present invention selects FGF family genes as an example to carry out the method for screening potential biomarkers of prostate cancer mentioned in the present invention. Detailed description. It should be noted that the following content about FGF family genes and their upstream miRNAs, software versions used, etc., should only be understood as a convenience for those skilled in the art to more comprehensively grasp the analysis method of the present invention, rather than for the screening method of the present invention limitations.

[0079] A method for screening potential biomarkers of prostate cancer, comprising the steps of:

[0080] (1) The prostate cancer data in the TCGA database were used to evaluate the expression levels of FGF family genes in prostate cancer and normal tissues. FGF family factors (FGF8, FGF13, FGF1...

Embodiment 2

[0098] Example 2 Analysis of FGF17 and FGF22 Expression in Prostate Cancer and Adjacent Cells

[0099] (1) Collect surgically resected prostate cancer tissues and paracancerous tissues from 46 prostate cancer patients, and sign informed consent with the patients;

[0100] (2) Freeze the tissue samples in liquid nitrogen within 30 minutes of isolation, and then transfer to -80°C;

[0101] (3) Use samples at -80°C for protein extraction and qRT-PCR experiments.

[0102] The result is as Figure 13 shown. The results showed that, compared with adjacent normal tissues, the expressions of FGF17 and FGF22 in prostate cancer tissues were significantly increased, and the difference was statistically significant (P<0.001).

[0103] Further, the prostate cancer cells C4-2, DU145, PC3 and normal prostate cells RWPE-1 were selected, and the expression levels of FGF17 and FGF22 were quantitatively detected by WB experiments, and the results were as follows: Figure 14 shown. The resul...

Embodiment 3

[0105]Example 3 Prostate cancer cell proliferation experiment

[0106] (1) RNA was extracted from PC3 and C4-2 cells and reverse transcribed, PCR amplified FGF17 cDNA and constructed into related vectors, sequenced and protein expression was verified, and the overexpression plasmid of FGF17 was obtained, and its effectiveness was verified by WB detection and specificity;

[0107] (2) Using the constructed FGF17 overexpression plasmid to transfect into PC3 and C4-2 cells, respectively, to construct and obtain PC3-FGF17 overexpression cells and C4-2-FGF17 overexpression cells;

[0108] (3) C4-2 cells, C4-2-FGF17 overexpression cells, PC3 cells and PC3-FGF17 overexpression cells were inoculated in 96 wells, each well was inoculated with 1×10 4 cells, three parallel wells for each cell;

[0109] (4) 24h, 48h, 72h and 96h after inoculation, the absorbance was detected by CCK-8 at 450nm to monitor the proliferation of cells.

[0110] The result is as Figure 15-16 shown. The re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for screening potential biomarkers of prostate cancer and application. According to the invention, deep and comprehensive bioinformatics analysis is carried out on prostatic cancer, a method for screening potential biomarkers of prostatic cancer is established, and potential targets of prostatic cancer can be rapidly, accurately and efficiently determined. The potential as a therapeutic target and a prognosis biomarker is evaluated on the basis of several large public databases, immune-related factors in a prostate cancer tumor microenvironment are found, and the regulation mechanism of the prostate cancer in the prostate cancer is further defined by further predicting the target through a network and finding upstream miRNA of the prostate cancer. And a practical theoretical basis and a scientific basis are provided for subsequent drug research and development, clinical treatment and the like of the prostatic cancer.

Description

technical field [0001] The invention belongs to the field of medical biology, and in particular relates to a method for screening potential biomarkers of prostate cancer and its application. Background technique [0002] Worldwide, the most common type of cancer in men is prostate cancer (PCa), with 174,650 new diagnoses in the United States in 2019, ranking second in cancer-related deaths. Treatment methods such as surgery and radical radiotherapy have a good effect on early localized prostate cancer, but for patients who cannot be treated by surgery or have metastases, endocrine therapy is often used clinically, and the median remission time of the treatment is 18-24 months Months later, it gradually developed into castration resistant prostate cancer (CRPC). [0003] With the in-depth study of the tumor microenvironment, it contains different types of cells, including proliferative tumor cells, endothelial cells, immune cells, fibroblasts, and mesenchymal stem cells (MSC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574G01N33/68C12Q1/6886C12N15/11G16B20/50G16B30/00G06F16/953A61K31/7105A61K45/00A61P35/00A61P35/04
CPCG01N33/57434G01N33/57484G01N33/68C12Q1/6886G16B20/50G16B30/00G06F16/953A61K45/00A61K31/7105A61P35/00A61P35/04C12Q2600/158C12Q2600/178G01N2333/50G01N2800/52
Inventor 李宇同陈果高白云潘斌
Owner THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com